Correlation of brain injury biomarkers with brain dysfunction, brain injury, and outcomes in critically ill patients: a post hoc exploratory analysis.
M Rühlmann, L Xu, M Bauer...
https://pubmed.ncbi.nlm.nih.gov/41973367/Actively Recruiting
Led by Jena University Hospital · Updated on 2024-12-30
100
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are investigating how reducing the complexity of the gut microbiome with broad spectrum antibiotics affects patients with severe infections or sepsis. This observational study focuses on the interactions between gut bacteria and the human host, looking closely at how changes in the microbiome may relate to brain dysfunction in both the short and long term. The study also examines differences in immune cell types and activation between younger and older patients with and without sepsis. The study involves collecting stool, rectal swabs, and blood plasma samples from critically ill patients, some treated with antibiotics like piperacillintazobactam or meropenem, and others not receiving antibiotic therapy during their ICU stay. Long-term survivors of sepsis, at least six months post-critical illness, are also included. Samples are taken at five time points day 1, day 7, and day 14 during ICU treatment, plus follow-ups at 3 and 6 months. Clinical, neuropsychological, and neuroimaging data are gathered to assess brain function. Participants undergo daily delirium screenings while in the ICU and cognitive tests at hospital discharge. During follow-ups, functional MRI and neuropsychological assessments are performed. The study tracks brain dysfunction from enrollment to 180 days and records secondary outcomes like survival, ICU days, days on respirators, and days needing vasopressor support. This comprehensive approach aims to connect microbiome changes to clinical outcomes and brain health over time.
CONDITIONS
The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units?
J
Johannes Ehler, Priv.-Doz. Dr. med.
K
Katrin Ludewig, Dr. med.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Jena University Hospital
Lead Sponsor
University of Jena
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 14 days during ICU stay
Participants in the ICU have stool, rectal swabs, and blood samples collected at three time points during ICU treatment to assess microbiome and immune cell changes along with daily delirium screening tests and cognitive assessments at discharge.
3 visits during ICU stay plus daily delirium screening
Duration - 6 months
Participants are followed up at 3 and 6 months after ICU inclusion with stool and blood samples collected, neuropsychological assessments, and brain imaging to evaluate long-term brain function and microbiome effects.
2 follow-up visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
M Rühlmann, L Xu, M Bauer...
https://pubmed.ncbi.nlm.nih.gov/41973367/Jena University Hospital
Lead Sponsor
University of Jena
Collaborating Sponsor